# iOnctura

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ionctura

- Industry: Biotechnology
- Headquarters: Geneva, Switzerland
- Website: www.ionctura.com
- Total disclosed funding: $108M
- Latest round: Series B (Jun 20, 2024)
- Investors on record: 7

## About

Based in Geneva, Switzerland, and founded in 2017 by co-founders Catherine Pickering, Ph.D. (CEO), and Lars van der Veen, Ph.D., iOnctura SA operates as a provider of small-molecule cancer therapies targeting the tumor-stroma-immune interface in healthcare institutions. In June 2024, iOnctura SA raised EUR 80 million in Series B funding led by Syncona Limited with participation from European Innovation Council, M Ventures, Inkef, Vi Partners, Schroders Capital, and 3B Future Health Fund.

The company provides a wide range of oncology therapies, such as PI3Kd inhibitors, autotaxin inhibitors, and TGF-ß pathway inhibitors. These therapies target immune resistance and fibrotic tumors across indications like uveal melanoma, pancreatic cancer, and solid tumors. Additionally, the firm also provides services such as clinical trials and research partnerships to advance oncology drug development.

## Funding rounds

- Series B, Jun 20, 2024, $86M — Schroders Capital, M Ventures, Vi Partners, Inkef, Syncona, 3B Future Health Fund, European Innovation Council
- Series A, Jul 14, 2020, $5.8M — Schroders Capital, M Ventures, Vi Partners, Inkef, 3B Future Health Fund
- Series A, Jan 23, 2020, $17M — Schroders Capital, M Ventures, Vi Partners, Inkef

## Investors

- Schroders Capital (https://capitalatlas.ai/funds/schroders-capital) — Series A, Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A, Series B
- Vi Partners (https://capitalatlas.ai/funds/vi-partners) — Series A, Series B
- Inkef (https://capitalatlas.ai/funds/inkef) — Series A, Series B
- 3B Future Health Fund (https://capitalatlas.ai/funds/3b-future-health-fund) — Series A, Series B
- Syncona (https://capitalatlas.ai/funds/syncona) — Series B
- European Innovation Council (https://capitalatlas.ai/funds/european-innovation-council) — Series B